Scholars Central

Conference abstractPublished 17 Oct 2016

Development of Targeted Therapies for Pancreatic Cancer

Authors: Pinku Mukherjee

University of North Carolina at Charlotte and Oncotab Inc.

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The study explores a novel strategy to deliver drugs to pancreatic ductal adenocarcinoma (PDA) to combat a) chemo-resistance and b) toxicity associated with systemic delivery of chemotherapeutic drugs. We also report the development of an accurate diagnostic/imaging test for PDA. Globally, this year, it is estimated that ~350,000 patients will die of PDA. Development of a biomarker for accurate diagnosis and targeted therapy to improve patient outcome are of paramount importance. Emerging evidence suggests that the capability of a tumor to propagate is dependent on a small subset of cells within the tumor, termed cancer stem cells (CSCs). Traditional treatments can miss the CSCs due to its quiescent property. We have developed a novel monoclonal antibody (designated TAB004) that recognizes a previously hidden cancer biomarker tMUC1 (tumor-specific MUC1). We have reported that tMUC1 is expressed on 95% of PDA and on all PDA-associated CSCs. In this study, we have covalently bound TAB004 to various drug-loaded PLGA (Poly lactic-co-glycolic acid) and silica-based nanoparticles (NPs). These formulations specifically target the tMUC1 on PDA, and associated CSCs sparing normal tissue. We hypothesize that NPs bound to TAB004 will enable the use of highly cytotoxic anti-cancer treatments at localized concentrations making the treatment more effective at lower doses, increasing its therapeutic index and limit toxicity. We will present the results on the localization and therapeutic efficacy of such formulations in appropriate mouse models. Further, we will report on the diagnostic/imaging application of TAB004 to monitor response to therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGastroenterology & Hepatology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Pinku Mukherjee”